A ngiomyolipoma (AML), the most common benign kidney tumor, is characterized by a unique histology, consisting of blood vessels, adipose tissue, and smooth muscle in varying proportions. 1, 2 Despite its benign histology, AML can result in severe hemorrhage or renal failure. 3 Furthermore, an aggressive variant, termed "epithelioid" AML, has been described and shown to possess metastatic potential. 4 AML is strongly associated with tuberous sclerosis complex (TSC), an autosomal dominant syndrome characterized by the emergence of benign tumors in various organs, including the kidneys, brain, and skin. TSC has been shown to result from mutations in TSC1 or TSC2, which code for hamartin or tuberin, respectively. The latter act as a tumor suppressor complex, inhibiting the activity of mammalian target of rapamycin complex 1 (mTORC1). mTORC1 is a key regulator of various cellular functions that acts to promote cell growth, protein synthesis, and vasculogenesis via phosphorylation of 2 main downstream effectors, S6K and 4EBP1. TSC1/2 loss of function leads to constitutive mTORC1 activation and aberrant cell growth. Despite the strong association with TSC, only 20% of AML patients have underlying TSC, and most cases arise sporadically. Several randomized controlled trials have demonstrated that mTORC1 inhibitors reduce the size of AML tumors in patients with TSC. Nonetheless, there are currently no available data regarding the efficacy of mTORC1 inhibition in treating sporadic AML, which represents the majority of cases. Interestingly, sporadic AMLs have been shown to harbor somatic TSC2 mutations and to exhibit mTORC1 activation. 5 In this study, we were interested in asking whether mTORC1 inhibition could be effective in treating not only TSC-associated AML, but also sporadic AML as well. First, we demonstrated that sporadic AML tumors indeed show activation of the mTORC1 pathway. Next, we treated a human sporadic AML cell line with rapamycin and showed that the treatment resulted in significant growth inhibition, to a similar extent to that seen when a human TSC-associated AML cell line is treated with rapamycin. Finally, to assess whether these results could be translated for use in the clinic, we detected a patient with large bilateral sporadic AMLs, which exhibited continued tumor growth following partial nephrectomy. Following the demonstration of mTORC1 activation in the patient's AML tissue, using pS6 staining, we treated her with rapamycin and followed tumor growth using magnetic resonance imaging. We detected significant and continued tumor shrinkage over several years, while exhibiting minimal side effects. In summary, we demonstrate that mTORC1 inhibitors may well represent an effective treatment for patients with sporadic AML, representing the majority of AML patients.
MATERIALS AND METHODS

See Supplementary Data.
RESULTS
Sporadic AML Exhibits Activation of the mTORC1 Pathway So as to validate that sporadic AML tumors show mTORC1 activation, which could serve as the basis for targeting this pathway in this group of patients, we first carried out immunohistochemical staining for pS6, a marker of mTORC1 activation in normal human adult kidneys (hAK), sporadic AML tumors, and TSC-related AML ( Figure 1 ). hAK demonstrated varying levels of pS6 expression, mostly in distal tubules (DT) and collecting ducts (CD) (Figure 1 ). Within the tumor tissue of sporadic AML specimens we detected a strong pS6 expression, whereas the normal kidney borders exhibited an expression pattern similar to that of hAK, involving mostly DT and CD. As expected, TSC-related AML demonstrated a strong pS6 expression in both tumor tissue and within normal kidney tissue, reflecting the germline mutation in TSC1/2 leading to widespread mTORC1 activation ( Figure 1 ). Taken together, these results indicate that the tumor tissue of sporadic AML exhibits strong activation of the mTORC1 pathway.
mTORC1 Inhibition Halts the In Vitro Growth of Human Sporadic AML Cells
Having shown enhanced mTORC1 activity in sporadic AML tumors, we next asked whether mTORC1 blockade would inhibit the growth of sporadic AML cells in vitro. For this purpose, we treated SV7Tert cells, representing a human sporadic AML cell line, 6, 7 with rapamycin for 96 hours. Treated SV7Tert cells demonstrated significant growth inhibition compared to vehicle-treated SV7Tert cells (Figure 2a) . In order to quantify this effect, we tested the viability of rapamycin-and vehicle-treated SV7Tert cells using the MTS assay. UMBSV-tel cells, representing a cell line derived from TSC-associated AML, served as control. We detected a significant reduction in cell viability in rapamycin-treated compared to vehicle-treated SV7Tert cells. Importantly, UMBSV-tel cells demonstrated a similarly significant reduction in proliferation following rapamycin treatment (Figure 2b ). Taken together, these results indicate that sporadic AML cells, similarly to TSCrelated AML cells, are sensitive to mTORC1 inhibition. exposed to excessive estrogen levels (e.g., oral contraceptives), known to promote AML growth. At this point, a workup for TSC was commenced. Brain MRI, chest CT, dermatological examination, and ophthalmological evaluation were unremarkable. Sanger sequencing of TSC1/2, encompassing the coding regions and their flanking regions (w50 bp from each side) yielded no mutation or polymorphism in TSC1 and no mutation in TSC2, where several known polymorphisms (Supplementary Data) were found. Multiplex ligation-dependent probe amplification excluded any deletion or duplication in TSC1/2. The patient was thus diagnosed with sporadic AML. MRI performed 1 year later identified continued tumor growth, now reaching 30 Â 50 mm.
The Patient's Tumor Demonstrates mTORC1 Activation
In order to assess whether the patient could benefit from mTORC1 inhibitors, we were interested in determining whether the tumors could result from mTORC1 overactivation. We therefore stained the patient's tumor for pS6 (Figure 2d ). We detected robust pS6 expression in all tumor compartments, similar to the results obtained in the staining of sporadic AML tumors of other patients (Figure 1 ).
Rapamycin Treatment Results in Significant Reduction in the Patient's AML Volume
Having demonstrated strong mTORC1 activation in the patient's AML, we decided to treat her with rapamycin at a dose of 1 mg/d, obtaining an average trough level of 3.7 ng/ml. MRI revealed significant and consistent reduction in tumor volume. Within 5 and 13 months from commencement of treatment, the tumor exhibited a 22.2% and 42.3% volume reduction, respectively, compared to baseline, measured 6 months prior to the beginning of treatment (Figure 2c) . Moreover, the hydronephrosis was resolved. The treatment resulted in transient mild stomatitis, hypercholesterolemia, and acne. Altogether, these results indicate that rapamycin is effective and safe in treating sporadic AML.
DISCUSSION
The understanding of AML pathogenesis has advanced significantly in recent years, mainly with the identification of mTORC1 as a key driving factor and integration of mTORC1 inhibitors into clinical use for TSC-associated AML. 8, 9 Nonetheless, because approximately 80% of cases are sporadic, 10 most AML patients have no pharmacological therapeutic option. A recent systematic analysis 10 found that among these patients, 92.7% require intervention, most commonly partial nephrectomy (37%) or embolization (29%). Moreover, although more recent data support a conservative approach in most patients, 11 tumor embolization results in re-intervention within 3 years in 36.5% of cases. 9 Furthermore, this strategy is obviously difficult to implement in non-TSC patients exhibiting multiple tumors. These issues underscore the need for noninvasive therapies for AML. Herein, we evaluated the potential of mTORC1 inhibition as such a method. Consistent with previous work, 5 we found that our patient's AML exhibited mTORC1 activation. Furthermore, we demonstrated that rapamycin effectively inhibits the growth of sporadic AML cells in vitro with efficacy similar to that seen in TSC-related AML cells. Importantly, rapamycin resulted in significant reduction in tumor volume and disappearance of hydronephrosis, and was well tolerated. Notably, although Kenerson et al. found mTORC1 activation in 15 of 15 sporadic AMLs, 5 TSC2 loss of heterozygosity could be detected only in 4 of 8 sporadic AMLs. 12 Thus, although empirical rapamycin treatment could be considered in light of the relatively safe side effect profile, acquisition of tumor sample and assessment of mTORC1 activity (e.g., via fine-needle aspiration 13 ) would allow a more definite indication for treatment.
In summary, we demonstrate that sporadic AML can be effectively treated using rapamycin. Although this concept needs to be proved in larger cohorts, we propose that the strong mTORC1 activity in sporadic AML and antiproliferative effect in vitro indicate that rapalogs should be considered for sporadic AML.
